Vivos Therapeutics Announces Third Quarter 2025 Results
Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) is gearing up to release its financial results for the third quarter of 2025. The announcement will take place after the market closes, allowing investors to reflect on the Company’s achievements and operational shifts.
Details of the Conference Call
Interested parties are invited to join the conference call at 5:00 p.m. Eastern Time. This session will be a platform for management to delve into the financial outcomes and discuss strategic developments that could affect future growth trajectories.
Engaging with Investors
To participate in the call, domestic callers can dial (800) 717-1738, while international participants can reach out at (646) 307-1865. For those who wish to review the call later, a replay will be accessible by calling (844) 512-2921 or (412) 317-6671 for international callers. The replay will remain available until a specified date in December 2025.
Webcast Access
A live webcast of the call will be hosted on Vivos' official website, providing a digital avenue for stakeholders to connect. The archive of this session will also be available for 30 days post-event, ensuring easy access to all the insights shared.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. is an innovative medical technology company dedicated to addressing sleep-related breathing disorders through its unique treatment methods. Their core focus lies in crafting revolutionary diagnostic tools and treatment options for conditions like obstructive sleep apnea (OSA), which impacts a massive population worldwide.
Innovative Solutions for OSA
Vivos’ groundbreaking devices have gained clearance from the U.S. Food and Drug Administration (FDA) for adult patients dealing with various severity levels of obstructive sleep apnea, and even moderate to severe OSA in children aged 6 to 17. Notably, the Complete Airway Repositioning and Expansion (CARE) devices are pioneering in the treatment of severe OSA among adults and were the first of their kind permitted for children.
Understanding OSA and Its Implications
Over 1 billion individuals globally suffer from OSA, yet an alarming 90% remain undiagnosed. This complex disorder extends beyond sleep disruptions, with connections to numerous chronic health challenges. Traditional treatments such as CPAP are mechanistic, not addressing the condition's root causes, leaving a significant treatment gap.
Vivos’ Mission
Founded in 2016 in Littleton, Colorado, Vivos aims to transform the landscape of sleep disorder management. The Company is dedicated to utilizing advanced technologies and forming strategic partnerships with healthcare providers, empowering them to cater to the intricate requirements of OSA patients effectively.
The Vivos Method
The Vivos Method represents a comprehensive approach tailored to treating OSA non-surgically, non-invasively, and without pharmaceuticals. This innovative methodology seeks to offer patients renewed hope and the opportunity to breathe new life.
Frequently Asked Questions
What is Vivos Therapeutics focused on?
Vivos Therapeutics focuses on developing solutions for sleep-related breathing disorders, mainly obstructive sleep apnea (OSA).
When is the scheduled conference call?
The conference call is set for 5:00 p.m. Eastern Time on the day of the financial results announcement.
How can investors access the conference call?
Investors can dial (800) 717-1738 for domestic access or (646) 307-1865 for international participants.
What are the benefits of Vivos' devices?
Vivos' devices provide innovative, FDA-cleared treatment options for severe OSA, focusing on addressing the root causes rather than just symptoms.
What is the Vivos Method?
The Vivos Method is a proprietary, clinically effective solution aimed at treating OSA without surgery or pharmaceuticals, offering hope for improved health outcomes.
